Callenbach Petra M C, Pels Lise P M, Mulder Paul G H, Linssen Wim H J P, Gooskens Rob H J M, van der Zwan Jan L, Brouwer Oebele F
Department of Neurology, University Medical Centre Groningen, University of Groningen, P.O. Box 30 001 9700 RB Groningen, The Netherlands.
Eur J Paediatr Neurol. 2007 Nov;11(6):325-30. doi: 10.1016/j.ejpn.2007.02.010. Epub 2007 Apr 10.
About 4-10% of children and adolescents suffer from migraine. In the last few years, several studies have been performed to assess the efficacy and safety of triptans for the acute treatment of migraine in children and adolescents. Only sumatriptan nasal spray has been approved for the treatment of acute migraine with or without aura in adolescents aged 12-17 years in Europe. This review describes the results of the studies with sumatriptan nasal spray that have been performed in children and adolescents, including a study performed in the Netherlands.
约4%至10%的儿童和青少年患有偏头痛。在过去几年中，已经开展了多项研究来评估曲坦类药物用于儿童和青少年偏头痛急性治疗的疗效和安全性。在欧洲，只有舒马曲坦鼻喷雾剂被批准用于治疗12至17岁青少年有或无先兆的急性偏头痛。本综述描述了在儿童和青少年中开展的使用舒马曲坦鼻喷雾剂的研究结果，包括在荷兰进行的一项研究。
